Boston Scientific has reached an agreement to acquire SoniVie, a medical device company developing the TIVUS Intravascular Ultrasound System, an investigational technology aimed at treating ...

RBC Capital Markets also lifted its price target to $116, citing Boston Scientific's strong initial guide for 2025 and solid execution as key drivers. Truist Securities echoed these sentiments ...

Despite the Marlborough medical device firm’s recent dealmaking hot streak, it says the growth in number of employees isn't due only to acquisitions. Boston Scientific Corp. grew its headcount ...

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Boston Scientific has agreed to buy the rest of privately held medical-device company SoniVie for an initial $360 million in a deal that expands its portfolio of interventional cardiology therapies.

Boston Scientific (BSX) has agreed to acquire medical device company SoniVie for around $360M upfront payment.